Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Aripiprazole was well tolerated in a pooled analysis of safety data from 932 patients with schizophrenia.

• Adverse event incidence rates for aripiprazole were similar to placebo and lower than haloperidol for certain side effects.
• Objective assessments showed no significant differences in extrapyramidal symptoms between aripiprazole and placebo.
• Aripiprazole resulted in significant reductions in abnormal involuntary movements compared to placebo.
• Mean weight change was minimal with aripiprazole (+0.71 kg) and haloperidol (+0.56 kg).
• Serum prolactin levels did not increase with aripiprazole, unlike with haloperidol.

AI simplified